Literature DB >> 7981456

Alternative mechanisms of action of anti-oestrogens.

A A Colletta1, J R Benson, M Baum.   

Abstract

The molecular mechanism of action of anti-oestrogens such as tamoxifen appears to be a complex mixture of antagonism of the mitogenic action of oestradiol at the level of the oestrogen receptor, plus a range of other activities from enzyme inhibition to growth factor modulation. This article will concentrate on two specific areas: 1) the inhibition of protein kinase C and calmodulin-dependent cAMP phosphodiesterase; and 2) the regulation by tamoxifen of peptide regulators of breast cancer epithelial cell growth such as insulin-like growth factor I (IGF I) and transforming growth factor beta (TGF-beta). The elucidation of these mechanisms is potentially important in the treatment and chemoprevention of breast cancer-the quantitative contribution of each individual mechanism of the overall antineoplastic action of anti-oestrogens is central to developing new and possibly more effective anti-oestrogens and optimizing strategies for their use.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981456     DOI: 10.1007/BF00689672

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  40 in total

1.  Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor.

Authors:  R L Sutherland; C K Watts; P C Ruenitz
Journal:  Biochem Biophys Res Commun       Date:  1986-10-30       Impact factor: 3.575

2.  Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin.

Authors:  G S Tannenbaum; W Gurd; M Lapointe; M Pollak
Journal:  Endocrinology       Date:  1992-06       Impact factor: 4.736

3.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.

Authors:  R L Sutherland; R E Hall; I W Taylor
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

4.  Desmoid tumours treated with triphenylethylenes.

Authors:  M D Brooks; S R Ebbs; A A Colletta; M Baum
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

5.  Insulin-like growth factor II mRNA expression in human breast cancer.

Authors:  D Yee; K J Cullen; S Paik; J F Perdue; B Hampton; A Schwartz; M E Lippman; N Rosen
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

6.  In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen.

Authors:  H T Huynh; E Tetenes; L Wallace; M Pollak
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

7.  Insulin-like growth factors stimulate chemotaxis in human melanoma cells.

Authors:  M L Stracke; E C Kohn; S A Aznavoorian; L L Wilson; D Salomon; H C Krutzsch; L A Liotta; E Schiffmann
Journal:  Biochem Biophys Res Commun       Date:  1988-06-30       Impact factor: 3.575

8.  Triphenylethylenes: a new class of protein kinase C inhibitors.

Authors:  C A O'Brian; R M Liskamp; D H Solomon; I B Weinstein
Journal:  J Natl Cancer Inst       Date:  1986-06       Impact factor: 13.506

Review 9.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

10.  Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.

Authors: 
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

View more
  13 in total

1.  Synthesis and biological activity of 3-N-substituted estrogen derivatives as breast cancer agents.

Authors:  Zhongliang Wan; Musiliyu A Musa; Patrick Joseph; John S Cooperwood
Journal:  Mini Rev Med Chem       Date:  2013-07       Impact factor: 3.862

2.  Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice.

Authors:  W M Wu; J L Suen; B F Lin; B L Chiang
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

3.  Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model.

Authors:  A C Mathew; T T Rajah; G M Hurt; S M Abbas Abidi; J J Dmytryk; J T Pento
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

4.  Synthesis and Pharmacological Evolution of Tetrahydroisoquinolines as Anti Breast Cancer Agents.

Authors:  Madhavi Gangapuram; Suresh Eyunni; Kinfe K Redda
Journal:  J Cancer Sci Ther       Date:  2014-04-25

5.  Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents.

Authors:  Rajendra P Tanpure; Amanda R Harkrider; Tracy E Strecker; Ernest Hamel; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2009-08-12       Impact factor: 3.641

6.  In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic drugs.

Authors:  Musiliyu A Musa; John S Cooperwood; M Omar F Khan; Taufiq Rahman
Journal:  Arch Pharm (Weinheim)       Date:  2010-11-29       Impact factor: 3.751

Review 7.  Role of TGF beta in the anti-estrogen response/resistance of human breast cancer.

Authors:  J R Benson; M Baum; A A Colletta
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-10       Impact factor: 2.673

8.  Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells.

Authors:  Susan M Dougherty; Williard Mazhawidza; Aimee R Bohn; Krista A Robinson; Kathleen A Mattingly; Kristy A Blankenship; Mary O Huff; William G McGregor; Carolyn M Klinge
Journal:  Endocr Relat Cancer       Date:  2006-03       Impact factor: 5.678

9.  Effects of tamoxifen on GH and IGF-I levels in acromegaly.

Authors:  R Cozzi; R Attanasio; G Oppizzi; P Orlandi; A Giustina; S Lodrini; N Da Re; D Dallabonzana
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

Review 10.  Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?

Authors:  Antoinette R Tan; Gabriela Alexe; Michael Reiss
Journal:  Breast Cancer Res Treat       Date:  2008-10-09       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.